Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial

ExteNET Study Group

Research output: Contribution to journalArticlepeer-review

252 Scopus citations

Fingerprint Dive into the research topics of 'Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial'. Together they form a unique fingerprint.

Medicine & Life Sciences